Valuation: Theracryf Plc

Market Cap 6.14M 5.4M 5.09M 4.64M 8.69M 589M 8.75M 61.09M 23.67M 300M 23.05M 22.55M 976M P/E 2026 *
-1.12x
P/E 2027 * -1.5x
Enterprise Value 3.98M 3.5M 3.3M 3.01M 5.63M 382M 5.67M 39.6M 15.35M 194M 14.94M 14.62M 633M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
64.1%
Yield 2026 *
-
Yield 2027 * -
1 day-2.86%
1 week-8.11%
Current month-10.53%
1 month-10.53%
3 months-27.66%
6 months-17.07%
Current year-15.00%
1 week 0.17
Extreme 0.17
0.18
1 month 0.16
Extreme 0.162
0.2
Current year 0.16
Extreme 0.16
0.27
1 year 0.16
Extreme 0.16
0.27
3 years 0.16
Extreme 0.16
2.2
5 years 0.16
Extreme 0.16
7.8
10 years 0.16
Extreme 0.16
30.25
Manager TitleAgeSince
Chief Executive Officer 64 2020-09-30
Director of Finance/CFO - 2023-09-04
Chief Tech/Sci/R&D Officer - 2021-04-30
Director TitleAgeSince
Director/Board Member - 2015-10-13
Director/Board Member 64 2020-09-30
Director/Board Member - 2023-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/16/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
5/22/25 Others

Director

422,727,272 19.8499%
3/4/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
-2.86%-8.11%-29.17%-92.77% 6.34M
-3.30%+1.19%+54.62%+104.15% 74.18B
-0.12%-3.82%+34.21%+74.86% 59.55B
+2.22%+5.46%+32.75%+21.51% 27.63B
+2.71%-1.96%-13.79%+364.46% 25.84B
+0.81%+0.61%-0.49%-5.14% 24.73B
-1.05%+1.07%+21.45%-10.32% 20.87B
-1.70%-3.35%+146.86%+325.69% 15.32B
+0.13%+1.08%-8.15%+498.59% 14.72B
+2.15%-0.92%+48.93%+169.79% 14.06B
Average -0.09%+0.16%+28.72%+145.08% 27.69B
Weighted average by Cap. -0.41%+0.58%+35.72%+132.06%

Financials

2026 *2027 *
Net sales - -
Net income -3.38M -2.97M -2.8M -2.56M -4.78M -324M -4.82M -33.62M -13.03M -165M -12.69M -12.41M -537M -3.46M -3.04M -2.87M -2.62M -4.89M -332M -4.93M -34.41M -13.33M -169M -12.98M -12.7M -550M
Net Debt -2.16M -1.9M -1.79M -1.63M -3.06M -207M -3.08M -21.49M -8.33M -106M -8.11M -7.93M -343M -704K -619K -584K -533K -996K -67.57M -1M -7M -2.71M -34.39M -2.64M -2.59M -112M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
26-09-24 GBX 0.1700 -2.86% 2,531,886
26-09-23 GBX 0.1750 0.00% 0
26-09-22 GBX 0.1750 0.00% 1,204,465
26-09-21 GBX 0.1750 0.00% 3,778
26-09-18 GBX 0.1750 -5.41% 5,733,950
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002247USD
Average target price
0.0162USD
Spread / Average Target
+622.25%

Annual profits - Rate of surprise